EP0912731A2 - Secreted proteins - Google Patents
Secreted proteinsInfo
- Publication number
- EP0912731A2 EP0912731A2 EP97922304A EP97922304A EP0912731A2 EP 0912731 A2 EP0912731 A2 EP 0912731A2 EP 97922304 A EP97922304 A EP 97922304A EP 97922304 A EP97922304 A EP 97922304A EP 0912731 A2 EP0912731 A2 EP 0912731A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- polynucleotide
- seq
- protein
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Definitions
- the present invention provides a composition comprising an isolated protein encoded by a polynucleotide selected from the group consisting of (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO.9,
- the present invention provides a composition comprising a protein, wherein said protein comprises an ammo acid sequence selected from the group consisting of
- L cells BHK, HL-60, U937, HaK or Jurkat cells.
- the protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein
- the resulting expressed protein may then be purified from such culture (i e , from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography
- the purification of the protein may also include an affinity column containing agents which will bind to the protein, one or more column steps over such affinity resins as concanavalin A-agarose, hepa ⁇ n-toyopearl ® or Cibacrom blue 3GA Sepharose ® , one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether, or immunoaffinity chromatography
- proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA)
- the efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).
- T-cell-dependent immunoglobulin responses and isotype switching include, without limitation, those described in Mahszewski, J Immunol 144 3028-3033, 1990, and Assays for B cell function In vitro antibody production, Mond. J J and Brunswick, M In Current Protocols in Immunology J E e a Coligan eds Vol 1 pp 3 8 1-3 8 16, John Wiley and Sons, Toronto 1994
- lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described m Darzynkiewicz et al , Cytometry 13 795-S08, 1992, Gorczyca et al , Leukemia 7 659-670, 1993, Gorczyca et al , Cancer Research 53 1945-1951 , 1993, Itoh et al , Cell 66 233-243, 1991 , Zacharchuk, Journal of Immunology 145 4037-4045, 1990, Zamai et al , Cytometry 14 891-897, 1993, Gorczyca et al , International Journal of Oncology 1 639-648, 1992
- compositions of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments.
- the compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differential ion of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair.
- the compositions of the invention may also be useful in the treatment of tendinitis, ca ⁇ al tunnel syndrome and other tendon or ligament defects.
- the activity of a protein of the invention may, among other means, be measured by the following methods
- Lactated Ringer's Injection or other vehicle as known in the art
- the pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art
- the amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0 01 ⁇ g to about 100 mg (preferably about 0 l ⁇ g to about 10 mg, more preferably about 0 1 ⁇ g to about 1 mg) of protein of the present invention per kg body weight
- a 50 50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns
- a sequestering agent such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix
- AAATNTTAAA ATAATTCCAA GCTGAGTTTT CTAGATTGAG CAGAAATGGT GAAAGGAGTA 120
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63432596A | 1996-04-18 | 1996-04-18 | |
US634325 | 1996-04-18 | ||
PCT/US1997/006139 WO1997039123A2 (en) | 1996-04-18 | 1997-04-14 | Secreted proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0912731A2 true EP0912731A2 (en) | 1999-05-06 |
Family
ID=24543331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97922304A Withdrawn EP0912731A2 (en) | 1996-04-18 | 1997-04-14 | Secreted proteins |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0912731A2 (ja) |
JP (1) | JP2001509004A (ja) |
AU (1) | AU2801697A (ja) |
WO (1) | WO1997039123A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6280739B1 (en) * | 1996-04-18 | 2001-08-28 | Genetics Institute, Inc. | Method of inhibiting angiogenesis using secreted proteins |
WO1999000408A2 (en) * | 1997-05-13 | 1999-01-07 | Incyte Pharmaceuticals, Inc. | Human transmembrane protein from the transmembrane 4 superfamily |
US5872234A (en) | 1997-06-27 | 1999-02-16 | Incyte Pharmaceuticals, Inc. | Human extracellular matrix proteins |
WO1999055863A1 (fr) * | 1998-04-28 | 1999-11-04 | Ono Pharmaceutical Co., Ltd. | Nouveau polypeptide, adnc le codant et son utilisation |
EP1141267A4 (en) * | 1998-12-23 | 2003-01-15 | Inst Genetics Llc | ELIMINATED PROTEINS |
CA2409342A1 (en) * | 2000-06-06 | 2001-12-13 | Incyte Genomics, Inc. | Extracellular messengers |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5550110A (en) * | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
-
1997
- 1997-04-14 AU AU28016/97A patent/AU2801697A/en not_active Abandoned
- 1997-04-14 WO PCT/US1997/006139 patent/WO1997039123A2/en not_active Application Discontinuation
- 1997-04-14 EP EP97922304A patent/EP0912731A2/en not_active Withdrawn
- 1997-04-14 JP JP53727097A patent/JP2001509004A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9739123A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2801697A (en) | 1997-11-07 |
WO1997039123A2 (en) | 1997-10-23 |
WO1997039123A3 (en) | 1998-02-26 |
JP2001509004A (ja) | 2001-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5723315A (en) | Secreted proteins and polynucleotides encoding them | |
WO1998007853A1 (en) | Secreted proteins and polynucleotides encoding them | |
CA2269755A1 (en) | Secreted proteins and polynucleotides encoding them | |
CA2289699A1 (en) | Secreted proteins and polynucleotides encoding them | |
US5728819A (en) | Secreted proteins and polynucleotides encoding them | |
EP0914430A2 (en) | Polynucleotides from human fetal brain encoding secreted proteins | |
EP0920499A2 (en) | Polynucleotides encoding secreted proteins | |
WO1997039122A2 (en) | ISOLATED AND CLONED MAST CELL 78 kDa PHOSPHOPROTEIN (MAST CELL DEGRANULATION INHIBITORY AGENT) AND USE THEREOF | |
WO1997039123A2 (en) | Secreted proteins | |
AU758823B2 (en) | Secreted proteins | |
WO1999000405A1 (en) | Secreted proteins | |
WO1997040151A2 (en) | Secreted proteins and polynucleotides encoding them | |
WO1997046685A1 (en) | Polynucleotides encoding secreted proteins from human dendritic cells | |
WO1998014470A2 (en) | Secreted proteins and polynucleotides encoding them | |
EP0922100A2 (en) | Secreted proteins and polynucleotides encoding them | |
WO1998001553A2 (en) | Secreted proteins and polynucleotides encoding them | |
EP0914429A1 (en) | Polynucleotides encoding secreted proteins from human pbmc | |
WO1998020130A2 (en) | Secreted proteins and polynucleotides encoding them | |
WO1997039030A2 (en) | Secreted proteins | |
WO1998007856A1 (en) | Secreted proteins and polynucleotides encoding them | |
CA2276063A1 (en) | Secreted proteins and polynucleotides encoding them | |
WO1998014575A1 (en) | Secreted proteins and polynucleotides encoding them________________________________________________________________________________________________________________________________________________ | |
WO1998004694A2 (en) | Secreted proteins and polynucleotides encoding them | |
WO1998004695A1 (en) | Secreted proteins and polynucleotides encoding them | |
EP0950102A1 (en) | Secreted proteins and polynucleotides encoding them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19981118 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SPAULDING, VIKKI Inventor name: MERBERG, DAVID Inventor name: LAVALLIE, EDWARD, R. Inventor name: RACIE, LISA, A. Inventor name: MCCOY, JOHN, M. Inventor name: JACOBS, KENNETH |
|
17Q | First examination report despatched |
Effective date: 20020326 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GENETICS INSTITUTE, LLC |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20030519 |